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Pobutamine Stress Echocardiography
n Patients With Diabetes Mellitus
nhanced Prognostic Prediction Using a Simple Risk Score
ithima Chaowalit, MD, Ana Lucia Arruda, MD, Robert B. McCully, MD, FACC, Kent R. Bailey, PHD,
atricia A. Pellikka, MD, FACC
ochester, Minnesota
OBJECTIVES We sought to determine the prognostic value of dobutamine stress echocardiography (DSE)
for predicting long-term outcomes in a large cohort with diabetes mellitus and to develop a
simple risk score using clinical and echocardiographic data.
BACKGROUND Neither risk scores nor long-term prognostic value of DSE has been described in a large
diabetic population.
METHODS We studied 2,349 patients with diabetes mellitus (1,338 men, 67  11 years of age) during
a follow-up of 5.4  2.2 years.
RESULTS Mortality and morbidity (myocardial infarction and late coronary revascularization) occurred
in 1,044 (44%) and 309 (13%) patients, respectively. Addition of stress echocardiographic
variables to the clinical and rest echocardiographic model provided incremental prognostic
information for predicting mortality (chi-square  243 to 270, p  0.0001) and morbidity
(chi-square  38 to 78, p  0.0001). For each end point, a simple risk score was derived
according to the estimated values of beta coefficients of multivariate predictors (insulin
therapy, smoking, failure to achieve target heart rate, percentage of ischemic segments, and
impaired left ventricular systolic function) and resulted in an assessment of risk among all age
groups. The C-statistic values were 0.60 to 0.64, indicating modest discrimination. The
estimated five-year event-free survivals of patients in three risk categories were 94%, 86%, and
80% for morbidity (p  0.00001) and 69%, 60%, and 47% for mortality (p  0.0001).
CONCLUSIONS In patients with diabetes mellitus, a simple and practical risk score using clinical variables and
results of DSE stratified patients into three risk groups for mortality and cardiovascular
morbidity. (J Am Coll Cardiol 2006;47:1029–36) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.048Cardiology Foundation
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batients with diabetes mellitus are at increased risk of
ortality and cardiovascular morbidity (1,2). Individuals
ith diabetes mellitus are more likely have clinical coronary
rtery disease (CAD), concomitant risk factors for CAD, an
symptomatic presentation, and a worse prognosis (3–7). As
result, multivessel CAD may not be recognized early,
ontributing to a worse prognosis (8). Early identification
nd risk stratification of CAD in patients with diabetes
ellitus is particularly essential in identifying those requir-
ng prompt and appropriate therapeutic intervention.
Clinical assessment of cardiac risk may be insufficient in
symptomatic patients with diabetes. Furthermore, inability
o exercise and failure to achieve an adequate workload may
imit the applicability of exercise stress testing in patients
ith diabetes mellitus (9). Dobutamine stress echocardiog-
aphy (DSE) is an accurate and reliable noninvasive tech-
ique used for the diagnostic and prognostic assessment of
AD (10–14). However, fewer data exist regarding the
ong-term prognostic role of DSE in a large cohort with
iabetes mellitus. The purposes of this study were to
etermine the prognostic value of DSE for predicting the
From the Mayo Clinic, Rochester, Minnesota. Dr. Chaowalit is currently affiliated
ith the Siriraj Hospital, Mahidol University, Bangkok, Thailand, and Dr. Arruda is
urrently affiliated with the Heart Institute (InCor), University of São Paulo Medical
chool, São Paulo, Brazil.m
Manuscript received October 14, 2004; revised manuscript received October 12,
005, accepted October 18, 2005.ong-term outcome in a large cohort with diabetes mellitus,
egardless of the presence of known or suspected CAD, and
o develop a simple model for risk stratification using
linical and stress echocardiographic data.
ETHODS
tudy population. Of 10,650 patients referred for clinically
ndicated DSE from January 1990 through December 2000,
e identified 2,618 (25%) patients with diabetes mellitus.
rom 1990 to 1997, diabetes mellitus was defined as fasting
lasma glucose level 140 mg/dl on at least two occasions
nd/or requirement for insulin or oral hypoglycemic agents
15). Patients who underwent DSE from 1998 to 2000 were
iagnosed as having diabetes mellitus according to the
riteria by the American Diabetes Association (16), includ-
ng fasting plasma glucose level 126 mg/dl. Two hundred
ixty-nine patients were excluded: 137 had inadequate
chocardiographic images, 128 international patients and
risoners were lost to follow-up, and 4 patients refused
esearch authorization. The remaining 2,349 (90%) patients
onstituted the study population.
Clinical characteristics and results of stress echocardiog-
aphy were recorded at the time of DSE. Hypertension was
efined as systolic blood pressure 140 mm Hg, diastolic
lood pressure 90 mm Hg, or the use of antihypertensive
edication. Patients were considered to have hyperlipid-
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DSE-Derived Risk Score in Patients With Diabetes March 7, 2006:1029–36mia if their total cholesterol was 200 mg/dl or if they
ere receiving lipid-lowering medication. Age as a cardio-
ascular risk factor was defined as 45 years for men and
55 years for women.
obutamine stress echocardiography. Dobutamine stress
chocardiography was performed according to a previously
escribed protocol using 3-min stages, a peak dose of 40
g/kg/min and atropine, to a total dose of 2 mg, as needed
o augment the heart rate (12). Contrast was used for
ndocardial border detection when two or more segments
ould not be adequately visualized. Ejection fraction was
valuated as previously described (17) or by visual estima-
ion. Impaired left ventricular systolic function was defined
s ejection fraction 50%. Wall motion was assessed and
cored 1 through 5 in each of 16 segments, and left
entricular wall motion score index was calculated at rest
nd peak stress (12,18). The development of new or
orsening wall motion abnormality (WMA), including a
eterioration of wall motion after an improvement at
ow-dose dobutamine, was considered inducible ischemia. A
esting WMA unchanged with dobutamine infusion or an
kinetic segment that became dyskinetic was defined as
xed (19,20). The percentage of abnormal segments (rest or
tress-induced abnormalities) was calculated at rest and
tress as the number of abnormal segments divided by the
umber of visualized segments, multiplied by 100. The
ercentage of ischemic segments was similarly derived.
ormal DSE was defined if there was no WMA at rest or
tress. Target heart rate was defined as 85% of age-predicted
aximal heart rate (220  age). The dose of dobutamine
nd heart rate at which the deterioration of wall motion first
ccurred were recorded. Ischemic threshold was defined as
he heart rate at which new or worsening WMA occurred,
ivided by the age-predicted maximal heart rate, multiplied
y 100%. The change in left ventricular end-systolic volume
LVESV) from rest to peak stress was recorded as normal
decrease in LVESV) or abnormal (increase or absence of a
ecrease). The stress electrocardiogram was positive for
schemia if there were horizontal or downsloping ST-
egment depression of 1 mm at 80 ms after the J-point in
he absence of baseline ST-segment deviation.
ollow-up. Follow-up information was obtained from med-
cal records, telephone interviews, mailed questionnaires, and
he Social Security Death Index. End points were all-cause
ortality and cardiovascular morbidity, defined as myocardial
nfarction (MI) and late (more than three months) coronary
evascularization. For the analysis of morbidity, patients who
Abbreviations and Acronyms
CAD  coronary artery disease
DSE  dobutamine stress echocardiography
LVESV  left ventricular end-systolic volume
MI  myocardial infarction
WMA  wall motion abnormalitynderwent coronary revascularization within three months after DSE were censored at the time of revascularization. For
atients who experienced both MI and late coronary revascu-
arization, only the first event was included for the analysis of
orbidity. The statistical analyses of all-cause mortality and
orbidity were performed separately.
tatistical analysis. Characteristics were summarized as
ercentages for categorical variables and as mean standard
eviation for continuous variables. Comparisons between
roups were based on Wilcoxon rank-sum test for contin-
ous variables and the Pearson chi-square test for categor-
cal variables. Cumulative probabilities of overall survival or
reedom from morbidity were estimated by the Kaplan-
eier method. For the event-free survival analysis, patients
ere censored at the time of non-cardiac death and at early
evascularization. Univariable and multivariable associations
f clinical and echocardiographic variables with the end
oints were assessed using the Cox proportional hazards
odel. All clinical variables and representative DSE vari-
bles were considered in the model, regardless of their
nivariate significance. The proportional hazards assump-
ion was tested by retaining the model-based risk score and
erforming a time-dependent proportional hazards analysis
n which the risk score was entered along with its interaction
oth with time and with log (time). Variables were selected
n a stepwise forward selection manner with entry and
etention set at a significance level of 0.05. Results of these
nalyses were summarized as hazard ratios with 95% con-
dence intervals. To determine the incremental value of
SE, models of: 1) clinical variables alone; 2) clinical and
est echocardiographic variables; and 3) clinical, rest, and
tress echocardiographic variables were compared via their
og likelihood ratio chi-square statistics. For each end point,
simple integer risk score was derived according to the
stimated values of beta coefficients of multivariable predic-
ors. The fitted model included age only for the purpose of
djustment; all other models were based on the variables
elected in the stepwise algorithm, which were replaced by
ichotomous versions to facilitate ease of clinical use. This
nteger risk score was then divided into three categories,
ased on choosing the split that maximized the three-group
og rank chi-square statistic, as well as the model chi-
quared statistic when age and the three risk categories were
ncluded in a proportional hazards model. Patients were
lassified as being at low, intermediate, and high risk
ccording to this categorization. The estimated five-year
vent survivals of each risk category were derived from the
aplan-Meier method. In addition, the best model for each
nd point using the original clinical and echocardiographic
ariables was summarized by way of its prediction of the
ne-, three-, five-, or eight-year probability of survival or
orbidity-free status, as a function of the respective model
ariables. This is included in the Appendix for users wishing
more accurate prediction model. Finally, the accuracy
calibration) of prediction models was assessed by dividing the
atient population into deciles of estimated risk, calculating the
verage proportional hazards model-based probabilities of
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March 7, 2006:1029–36 DSE-Derived Risk Score in Patients With Diabetesurvival or morbidity-free status at each time point within these
eciles, and comparing them with the corresponding Kaplan-
eier (model-free) estimates of the probabilities within the
ame deciles of risk. To assess the predictive power of each
odel, the C-statistic for censored data was calculated and
eported for each model. Analyses were carried out using SAS
ersion 8.2 (SAS Institute Inc., Cary, North Carolina).
ESULTS
tudy population. Of 2,349 patients, 1,338 (57%) were
en; age was 67  11 years. Indications for DSE were for
reoperative cardiac risk assessment in 1,166 (50%), evalu-
tion of known or suspected CAD in 1,076 (46%), and
ther in 106 (4%) patients. Reasons for inability to exercise
able 1. Clinical Characteristics
Variables
Ischemic
DSE
Non-Ischemic
DSE
p Valuen  1,007 n  1,342
ge (yrs) 68  10 67  12 0.006
ale gender 634 (63) 704 (52) 0.0001
ypertension 758 (75) 952 (71) 0.02
nsulin therapy 503 (50) 612 (46) 0.04
moking 648 (64) 817 (61) 0.09
amily history of CAD 435 (43) 496 (37) 0.002
rior MI 356 (35) 289 (22) 0.0001
rior revascularization 355 (35) 298 (22) 0.0001
ndication for testing 0.48
Preoperative assessment 491 (49) 675 (50)
Evaluation of known or
suspected CAD
474 (47) 602 (45)
Other 42 (4) 65 (5)
easons for test termination 0.0001
Achieving target heart
rate
666 (66) 983 (73)
Ischemia 128 (13) 14 (1)
Completion of protocol 101 (10) 186 (14)
Adverse effects 112 (11) 159 (12)
esults are expressed as number (%) of patients or as mean  standard deviation.
CAD  coronary artery disease; DSE  dobutamine stress echocardiography;
I  myocardial infarction.
able 2. Dobutamine Stress Echocardiographic Data
Variables
All-Cause Mor
Event
n  1,044
No Even
n  1,305
est heart rate (beats/min) 73  13 73  13
eak heart rate (beats/min) 126  17 131  16
jection fraction (%) 51  15 56  12
arget heart rate achieved 726 (70) 1,020 (78)
ositive stress ECG 112 (11) 121 (9)
bnormal LVESV response 205 (20) 129 (10)
bnormal DSE 765 (73) 740 (57)
schemic DSE 502 (48) 505 (39)
ercent ischemic segments 14  19 10  17
est percent abnormal segments 32  35 19  29
eak percent abnormal segments 38  34 24  30
est WMSI 1.5  0.6 1.3  0.4
eak WMSI 1.6  0.6 1.4  0.5esults are expressed as number (%) of patients and mean  standard deviation.
DSE  dobutamine stress echocardiography; ECG  electrocardiogram; LVESV  leere peripheral vascular disease in 711 (30%), orthopedic
imitations in 603 (26%), debility in 214 (9%), pulmonary
isease in 112 (5%), and other in 709 (30%) patients. Of
,349 patients, 1,115 (47%) were receiving insulin (with or
ithout concomitant oral hypoglycemic agents), whereas
40 (32%) and 494 (21%) patients were receiving oral
ypoglycemic agents and diet control only, respectively.
ardiovascular risk factors included age in 91% (60% men,
0% women), hypertension in 73%, smoking in 62%,
yperlipidemia in 56%, and family history of CAD in 40%.
istory of CAD, prior MI, and prior revascularization were
resent in 47%, 27%, and 28%, respectively. Clinical char-
cteristics, according to results of DSE, are shown in
able 1.
est and DSE data. The peak dose of dobutamine infu-
ion was 34 9 g/kg/min. Atropine, 0.84 0.61 mg, was
dministered to 910 (41%) patients. Six hundred three
26%) patients did not achieve target heart rate; among
hese, 262 (43%) were on beta-blockers. Heart rate increased
rom 73  13 beats/min to 128  16 beats/min. The stress
lectrocardiogram was positive in 233 (10%) patients. At
est, the ejection fraction was 54  14% and systolic
unction was impaired in 589 (25%) patients. Resting
MA was present in 1,238 (53%) patients; among these,
14 (33%) reported no history of CAD. Ejection fraction
ncreased from 54 14% at rest to 64 17% at peak stress.
he DSE was abnormal in 1,505 (64%) patients. Inducible
schemia developed in 1,007 (43%) patients. Of 1,111
atients with no resting WMA, inducible ischemia devel-
ped in 267 (24%) patients. Ischemic threshold was 74 
3%, detected at a heart rate of 111  19 beats/min and a
obutamine infusion rate of 30  10 g /kg/min. An abnor-
al LVESV response was noted in 334 (14%) patients.
utcomes. Follow-up periods for all-cause mortality and
ardiovascular morbidity were 5.4  2.2 (maximum, 13.2)
ears and 3.9  2.7 (maximum, 13.2) years, respectively.
eath occurred in 1,044 (44%) patients. Survival probabil-
Cardiovascular Morbidity
p Value
Event
n  309
No Event
n  2,040 p Value
0.8 72  13 74  13 0.007
0.0001 127  15 129  17 0.001
0.0001 53  12 54  14 0.16
0.0001 216 (70) 1,530 (75) 0.055
0.2 30 (10) 203 (10) 0.88
0.0001 61 (20) 283 (13) 0.003
0.0001 204 (73) 1,301 (63) 0.0001
0.0001 150 (54) 857 (41) 0.0001
0.0001 16  21 11  17 0.0001
0.0001 25  30 25  33 0.087
0.0001 35  32 30  33 0.0001
0.0001 1.4  0.5 1.4  0.5 0.08
0.0001 1.5  0.5 1.5  0.5 0.0001tality
tft ventricular end-systolic volume; WMSI  wall motion score index.
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DSE-Derived Risk Score in Patients With Diabetes March 7, 2006:1029–36ties at 1, 3, 5, and 8 years were 89%, 74%, 60%, and 44%,
espectively. The cumulative mortality rate was higher in
atients with abnormal compared with patients with normal
SE at 1 year (13% vs. 7%), 3 years (30% vs. 19%), 5 years
45% vs. 31%), and 8 years (61% vs. 48%) (p  0.0001).
atients on insulin had lower survival probabilities com-
ared with patients who were on oral agents or diet alone
87% vs. 90% at 1 year, 71% vs. 76% at 3 years, 57% vs. 62%
t 5 years, 42% vs. 46% at 8 years; p  0.005).
Cardiovascular morbidity occurred in 309 (13%) patients;
93 had MI and 116 had late coronary revascularization.
arly coronary revascularization (with no intervening event)
as performed in 148 patients. Patients with inducible
schemia were more likely to undergo coronary revascular-
zation than those with nonischemic DSE (19% vs. 9%, p
.0001). The DSE data of patients with and without
ortality and cardiovascular morbidity are shown in Table 2.
redictors of outcomes. Variables associated with an in-
reased risk of mortality and cardiovascular morbidity in
nivariate and multivariate analysis are listed in Tables 3
nd 4, respectively. All variables from Table 1 and repre-
able 3. Predictors of All-Cause Mortality
Variables
Univariate Analysis
HR 95% CI Chi-Square
ge* 1.39 1.30–1.48 114
nsulin therapy 1.16 1.02–1.31 5
rior MI 1.47 1.30–1.67 34
rior revascularization 1.25 1.10–1.37 11
moking 1.22 1.08–1.39 10
est ejection fraction† 0.80 0.77–0.83 104
bnormal stress LVESV 1.79 1.53–2.08 49
ailure to achieve target heart rate 1.29 1.13–1.47 14
ercent ischemic segments† 1.08 1.05–1.12 22
est percent abnormal segments† 1.09 1.07–1.11 91
eak percent abnormal segments† 1.10 1.08–1.12 105
est WMSI‡ 1.15 1.12–1.18 90
eak WMSI‡ 1.15 1.12–1.18 105
verall chi-square value for multivariate analysis  273; p  0.0001. *Per decade; †
schemic segments 25%
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1
able 4. Predictors of Cardiovascular Morbidity
Variables
Univariate Analysis
HR 95% CI Chi-Square
ge* 1.24 1.11–1.14 14.7
ypertension 1.49 1.13–1.96 7.9
rior MI 1.49 1.18–1.89 10
rior revascularization 1.54 1.19–1.90 11.7
est ejection fraction† 0.89 0.82–0.96 7.86
bnormal stress LVESV 2.11 1.40–2.57 27.2
ailure to achieve target heart rate 1.49 1.15–1.87 9.57
ercent ischemic segments† 1.20 1.14–1.26 44.5
est percent abnormal segments† 1.00 1.00–1.01 6.57
eak percent abnormal segments† 1.01 1.01–1.02 31.28
est WMSI‡ 1.07 1.02–1.33 6.55
eak WMSI‡ 1.14 1.11–1.20 26.84verall chi-square value for a multivariate analysis  57; p  0.0001. *Per decade; †per 1
Abbreviations as in Table 3.entative variables from Table 2 were considered in the
ultivariate analysis. In multivariate analysis, age, failure to
chieve target heart rate, and the percentage of ischemic
egments were important predictors of both mortality and
orbidity. Table 5 shows the incremental prognostic value
f DSE over clinical and rest echocardiographic variables for
redicting mortality and morbidity. The Kaplan-Meier
urves for overall survival according to the test result and
xtent of inducible ischemia are illustrated in Figure 1.
atients with inducible ischemia were at an increased risk of
ortality; risk was higher in those with more extensive
schemia. When the proportional hazards assumption was
ested, there was no evidence for lack of proportionality for
ither end point based on the models in Tables 3 and 4.
simple risk score for risk stratification. ALL-CAUSE
ORTALITY. Multivariate predictors of mortality were used
o develop a risk score. The continuous variables, rest
jection fraction and percentage of ischemic segments, were
ichotomized using cut points of 50% and 25%, respec-
ively. Age group was used to further classify patients in
ach risk category. The risk score was based on assigning
Multivariate Analysis
Risk ScoreValue HR 95% CI Chi-Square p Value
0.0001 1.45 1.35–1.55 125 0.0001
0.02 1.28 1.13–1.45 14 0.0001 1
0.0001
0.001
0.002 1.30 1.13–1.49 13 0.0003 1
0.0001 0.85 0.78–0.93 14 0.0002 3§
0.0001
0.0002 1.29 1.12–1.48 13 0.0004 1
0.0001 1.10 1.04–1.15 12 0.0005 2
0.0001
0.0001
0.0001
0.0001
% increment; ‡per 0.25-U increment; §if ejection fraction 50%; if percentage of
Multivariate Analysis
Risk ScoreValue HR 95% CI Chi-Square p Value
0.0001 1.26 1.13–1.42 16.8 .0001
0.005 1.33 1.01–1.76 4.1 0.042 1
0.001 1.27 1.00–1.62 3.9 0.047 1
0.001
0.005
0.0001
0.002 1.49 1.16–1.91 9.8 0.001 2
0.0001 1.19 1.12–1.25 37.9 0.0001 3§
0.010
0.0001
0.011
0.0001p









per 10p




0% increment; ‡per 0.25-U increment; §if percentage of ischemia segments 25%.
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March 7, 2006:1029–36 DSE-Derived Risk Score in Patients With Diabeteseights to each variable according to their parameter
stimates from the Cox proportional hazard model, includ-
ng: 1 point each for insulin therapy, smoking, or failure to
chieve target heart rate; 2 points if the percentage of
schemic segments was25%, and 3 points for impaired left
entricular systolic function (Table 3). Patients were then
lassified into three risk categories according to their
ummed risk score (0 to 1, 2 to 3, and4, respectively). The
oefficient of the risk score for mortality was similar in
atients with or without known CAD (hazard ratio, 1.2 and
.2; p 0.0001 for each). The C-statistic of this simple risk
core model was 0.60. The corresponding mortality rates per
erson-year of follow-up were 7%, 10%, and 16%, respec-
ively. The estimated five-year survivals of patients in the
hree risk categories were 69%, 60%, and 47% (p 0.0001).
he Kaplan-Meier survival curves of patients in these three
isk categories are shown in Figure 2. The predictive value
able 5. Independent Predictors of All-Cause Mortality and Car
Models Variable
ll-cause mortality
Clinical Age*
Male gender
Hypertension
Insulin therapy
Smoking
Prior MI
Clinical  rest echo Rest ejection fraction
Clinical, rest echo  stress echocardiography Failure to achieve tar
Percent ischemic seg
ardiovascular morbidity
Clinical Age*
Male gender
Hypertension
Insulin therapy
Smoking
Prior MI
Clinical  rest echo Rest ejection fraction
Clinical, rest echo  stress echocardiography Percent ischemic seg
Failure to achieve tar
Per decade; †per 10% increment.
Abbreviations as in Table 3.
igure 1. Kaplan-Meier survival curves for patients with diabetes mellitus
ccording to the test result and extent of inducible ischemia. % isch  the
ercentage of ischemic segments.
F
af this mortality risk score was independent of age (p 
.0001). Figure 3 shows the estimated five-year mortality in
he subsets of patients according to age group and risk
ategory.
ARDIOVASCULAR MORBIDITY. We assigned 1 point each
or prior MI and hypertension, 2 points for failure to achieve
arget heart rate, and 3 points if the percentage of ischemic
egments was 25% (Table 4). The coefficient of the risk
core for morbidity was similar in patients both with and
ithout coronary artery disease (hazard ratio, 1.2, p 
.0002; and 1.3, p 0.0001; respectively). A risk score of 0,
to 2, or 3 permitted classification of patients into three
isk categories. This C-statistic of this model was 0.62. The
vent rates per person-year of follow-up of patients in the
hree risk categories were 2%, 3%, and 6%. The estimated
ve-year probability of remaining free of an ischemic event
scular Morbidity Using a Three-Step Model
HR 95% CI p Value Model Chi-Square
1.43 1.34–1.53 0.0001 174
1.01 0.89–1.16 0.8
1.05 0.92–1.21 0.5
1.30 1.15–1.47 0.0001
1.30 1.13–1.50 0.0002
1.36 1.20–1.55 0.0001
0.82 0.78–0.86 0.0001 243
eart rate 1.29 1.13–1.48 0.0003 270
† 1.06 1.03–1.10 0.0003
1.24 1.01–1.39 0.0002 35
1.18 0.87–1.43 0.38
1.44 1.09–1.90 0.01
1.19 0.95–1.50 0.13
1.14 0.88–1.46 0.32
1.37 1.08–1.75 0.009
0.94 0.86–1.03 0.16 38
† 1.18 1.12–1.25 0.0001 78
eart rate 1.48 1.15–1.90 0.002diova
s
†
get h
ments
†
ments
get higure 2. Kaplan-Meier survival curves for patients with diabetes mellitus
ccording to the risk category.
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DSE-Derived Risk Score in Patients With Diabetes March 7, 2006:1029–36excluding early revascularization) of patients in the three
isk categories were 94%, 86%, and 80% (p  0.0001).
An exact model-based prediction for each end point using
he continuous risk models of Tables 3 and 4 is described in
he Appendix. The C-statistic for each model was 0.64.
hen these model-based probabilities were averaged within
odel-based deciles of risk and compared directly with the
aplan-Meier based probabilities for the same time points
nd deciles, the 40 discrepancies were within 3% more than
0% of the time for both end points. There was no
ystematic overestimation or underestimation of risk among
he groups.
ISCUSSION
lthough the diagnostic and prognostic role of DSE in
valuation of CAD is well established, less is known about
ts incremental value for predicting long-term outcomes in a
arge cohort of diabetic patients. This study shows the
rognostic value of DSE in 2,349 patients with diabetes
ellitus during a follow-up of up to 13 years. The mortality
nd cardiovascular morbidity were significantly higher in
atients with abnormal or ischemic test results. Also, failure
o achieve target heart rate and percentage of ischemic
egments, an indicator of the extent of inducible ischemia,
ere independent predictors and incremental to clinical and
est echocardiographic variables for predicting adverse long-
erm outcomes. Simple, practical risk scores for risk strati-
cation were developed. These models should be applied to
mprove treatment strategies for patients who are at high
isk.
linical importance of a high mortality rate in patients
ith diabetes mellitus. In the present study, the mortality
ate of patients with diabetes mellitus was higher than that
n a recent study by Sozzi et al. (44% vs. 24%) (21). Several
opulation-based studies of patients with diabetes mellitus,
hich showed mortality rates of 20% to 48% during
igure 3. The estimated five-year mortality, derived from the Kaplan-
eier method, for patients with diabetes mellitus according to age group
nd risk category.ollow-up of 5 to 10 years (22–24), provide evidence for the idverse impact of diabetes mellitus on mortality. Cardio-
ascular mortality has been shown to account for the
ajority of deaths in diabetic patients. Although direct
omparisons across these studies are problematic because of
ifferences in baseline characteristics and follow-up dura-
ion, the mortality rate is substantial in patients with
iabetes mellitus. Therefore, accurate risk stratification is
mportant for optimal patient management.
The present study develops the prognostic information
rom DSE in patients with diabetes mellitus using a risk
core that combines both echocardiographic and clinical
ariables. This score, which divides patients into three
ategories, is sufficiently simple for use in clinical practice.
In our study, patients with diabetes mellitus had a high
revalence of CAD risk factors and prior MI, reflecting a
igh-risk population. Furthermore, inability to exercise in
atients with diabetes mellitus, the reason for DSE rather
han exercise testing, is a marker not only of a high pretest
robability of CAD but also of a poorer prognosis (25,26).
ven patients in the lowest risk group had substantial
ortality. As a consequence of a long duration of follow-up,
he progression of non-obstructive coronary lesions and the
evelopment of new obstructive lesions may also contribute
o high event rates. The present study also found that
urvival probabilities were lower in patients on insulin.
owever, this may be related to the severity of diabetes
ellitus rather than to an effect of therapy.
ole of DSE in the diabetic population. Myocardial
erfusion scintigraphy has been recommended by the
merican Diabetes Association and the American College
f Cardiology for the evaluation of CAD in patients with
iabetes mellitus (27). Because of the paucity of outcome
ata, the prognostic role of stress echocardiography in
atients with diabetes mellitus was not established. Since
hen, more information regarding the role of stress echo-
ardiography (exercise, dobutamine, dipyridamole, or com-
ination) in patients with diabetes has become available
21,22,28–32). Our findings validate the prognostic signif-
cance of DSE in predicting long-term outcomes in a large
ohort with diabetes mellitus and provide a simple approach
or clinical risk stratification.
tudy limitations. Data regarding types, duration, compli-
ations of diabetes mellitus, degree of glycemic control, and
hanges in medications after the DSE were not available.
lso, criteria for diagnosis of diabetes mellitus evolved
uring the time period of the study (16). To avoid inaccu-
acy in defining causes of death, all-cause mortality was
elected as an unbiased, objective end point (33). Data on
ancer or history of congestive heart failure, important
ontributors to mortality, were not available in this study.
o focus on the prognostic significance of DSE on cardiac
utcomes, we regarded MI and coronary revascularization as
ardiovascular morbidity, which was analyzed separately.
t is possible, especially in this population with diabetes
ellitus, that some patients may have had myocardialnfarction that was not clinically recognized. Post-test re-
f
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March 7, 2006:1029–36 DSE-Derived Risk Score in Patients With Diabeteserral bias likely influenced the decision to perform coronary
evascularization. Although we excluded early revasculariza-
ion for this reason, it is possible that test results influenced
he decision for late revascularization. Nevertheless, DSE
rovided similar incremental value in predicting both all-
ause mortality and cardiovascular morbidity. The present
tudy provides simple risk scores for risk stratification in
atients with diabetes mellitus. However, the C-statistic
alues of 0.60 to 0.64 for the various models presented
ndicate modest discrimination. External validity testing
ith independent samples, ideally from different institu-
ions, would be desirable.
ONCLUSIONS
he present data verify the prognostic significance of DSE in
redicting mortality and cardiovascular morbidity during a
ong follow-up period in a large cohort of patients with
iabetes mellitus. The extent of inducible ischemia and inad-
quate chronotropic response showed a strong association with
orse outcomes, independent and incremental to clinical and
est echocardiographic data. The simple risk scores developed
n this study may be applied to the assessment of risk category
n patients with diabetes mellitus.
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